RTY 694
Alternative Names: RTY-694Latest Information Update: 07 Jan 2025
Price :
$50 *
At a glance
- Originator Rectify Pharma
- Class
- Mechanism of Action ATP-binding cassette transporter modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Primary sclerosing cholangitis
Most Recent Events
- 18 Nov 2024 Pharmacodynamics data from a preclinical trial in Primary sclerosing cholangitis released by Rectify pharmaceuticals
- 18 Nov 2024 Rectify Pharmaceuticals plans a Clinical trial for Primary sclerosing cholangitis
- 22 Oct 2024 Preclinical trials in Primary sclerosing cholangitis in USA (unspecified route), before October 2024